In the Literature

Leah LawrenceAcute Lymphoblastic Leukemia | February 2, 2023
Efforts should focus on initiating use of physical therapy for inpatient pediatric ALL patients, research shows.
Leah LawrenceAcute Lymphoblastic Leukemia | February 2, 2023
Most pediatric patients with ALL achieved complete response after treatment with CD19 CAR T-cell therapy.
Leah LawrenceAcute Lymphoblastic Leukemia | February 2, 2023
Inotuzumab ozogamicin resulted in a high overall response rate, and many ALL patients achieved MRD negativity.
Advertisement
Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022
Certain CD19 chimeric antigen receptor (CAR) T-cell products were associated with different levels of adverse events and ...
Leah LawrenceMyeloma | November 14, 2022
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Leah LawrenceChronic Lymphocytic Leukemia | February 1, 2023
Even after COVID-19 vaccination, non-Hodgkin lymphoma or CLL patients had low antibody binding and live-virus neutralization.
Advertisement
Leah LawrenceMyeloma | November 14, 2022
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
Certain geriatric assessment measures were associated with survival among older adults with acute myeloid leukemia.
Leah LawrenceTransplantation & Cellular Therapy | November 14, 2022
A study of seven clinical trials around CAR T-cell therapies showed a substantially low enrollment of participants who were ...
Leah LawrenceMyeloma | November 14, 2022
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
Leah LawrenceT-Cell Lymphoma | November 14, 2022
Researchers inactivated thousands of genes in several adult T-cell leukemia/lymphoma cell lines and found CDK6 to be a ...
Leah LawrenceAcute Lymphoblastic Leukemia | February 2, 2023
Study shows that CD19-directed CAR T-cell therapy may be potential treatment for B-ALL patients with CNS leukemia.
Leah LawrenceChronic Lymphocytic Leukemia | February 2, 2023
First-line ibrutinib has sustained survival benefit for patients with CLL, according to a long-term follow-up study.
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
For AML patients who had hematopoietic stem cell transplantation, certain IDH mutations may increase their relapse risk.
Sabrina AhleChronic Myeloid Leukemia | November 14, 2022
Researchers shared additional data on the immune response of patients with chronic myeloid leukemia to COVID-19 infection and ...
Sabrina AhleChronic Myeloid Leukemia | November 22, 2022
At least one-quarter of patients experienced arterial occlusive events (AOE), but rates varied depending on the approach.
Sabrina AhleChronic Myeloid Leukemia | November 14, 2022
Researchers surveyed the reasons for low recruitment and early closure of the UK National Cancer Research Institute’s ...
Sabrina AhleHodgkin Lymphoma | November 14, 2022
Researchers examined survival rates by age in patients with Hodgkin lymphoma receiving response-adapted therapy on ...
Sabrina AhleMyeloproliferative Neoplasms | May 30, 2023
In patients with high-risk essential thrombocythemia and polycythemia vera, both hydroxyurea and pegylated interferon-α.
Sabrina AhleMyeloma | November 14, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Advertisement
Advertisement
Editorial Board